Clinical Trial

TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

Suspended Phase 1/2
View on ClinicalTrials.gov →
Why the trial stopped
PI Request
Summary
This is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and metastatic pancreatic cancer. The primary objectives are to assess safety and determine the recommended Phase II dose (RP2D).
Protocol Amendment History 3 changes
critical Recruitment suspended 2026-08-01
critical Recruitment suspended: PI Request 2026-08-01
critical Recruitment opened 2026-06-12
Trial Details
NCT Number NCT07377526
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: United States Department of Defense
Conditions Pancreatic Cancer
Enrollment 37 participants
Start Date 2026-05-26
Primary Completion 2028-03-01 (estimated)
Study Completion 2030-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-31